Oct 18 (Reuters) - Novartis AG:
* CEO SAYS HOPES SANDOZ RETURN TO GROWTH IN “NEAR FUTURE” DRIVEN BY BIOSIMILARS
* CEO SAYS LUTHATHERA DRUG HAS POTENTIAL FOR SALES OF MORE THAN $1 BILLION, MORE THAN DEAL CASE
* NOVARTIS AG CEO SAYS ENTRESTO PERFORMING AHEAD OF EXPECTATIONS, HAS SALES POTENTIAL OF $5 BLN IN PRESERVED, REDUCED EJECTION FRACTION HEART FAILURE
* NOVARTIS AG NOVN.S CEO SAYS 15 AVXS-101-TREATED PATIENTS ARE ALL ‘ALIVE, THRIVING,’ SAYS CONFIDENT GENE THERAPY WILL BECOME ‘FOUNDATIONAL’ THERAPY
* NOVARTIS AG NOVN.S CEO SAYS 15 AVXS-101-TREATED PATIENTS ARE ALL ‘ALIVE, THRIVING,’ SAYS CONFIDENT GENE THERAPY WILL BECOME ‘FOUNDATIONAL’ THERAPY
* NOVARTIS AG NOVN.S CEO SAYS $2.1 BLN ACQUISITION OF ENDOCYTE ECYT.O ADDS POTENTIAL BLOCKBUSTER DRUG TO PORTFOLIO Source text for Eikon: Further company coverage: (Reporting by John Miller)
